Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice

P. Pérez-Torre , J.L. López-Sendón , V. Mañanes Barral , I. Parees , S. Fanjul-Arbós , E. Monreal , A. Alonso-Canovas , J.C. Martínez Castrillo
{"title":"Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice","authors":"P. Pérez-Torre ,&nbsp;J.L. López-Sendón ,&nbsp;V. Mañanes Barral ,&nbsp;I. Parees ,&nbsp;S. Fanjul-Arbós ,&nbsp;E. Monreal ,&nbsp;A. Alonso-Canovas ,&nbsp;J.C. Martínez Castrillo","doi":"10.1016/j.nrleng.2021.08.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and purpose</h3><p>The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life.</p></div><div><h3>Methods</h3><p>We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs.</p></div><div><h3>Results</h3><p>Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years<!--> <!-->±<!--> <!-->8.43 and H&amp;Y stage was 3 [2–4]. Mean dose of levodopa used was 703.75<!--> <!-->mg<!--> <!-->±<!--> <!-->233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation.</p></div><div><h3>Conclusions</h3><p>Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 4","pages":"Pages 340-344"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000361/pdfft?md5=2257d8b81f4fd87afd9a8edc2202ed0c&pid=1-s2.0-S2173580824000361-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173580824000361","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose

The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life.

Methods

We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for. Also, we collected time of simultaneous use, doses of levodopa and other antiparkinsonian drugs.

Results

Clinical records were reviewed for the study period of September 2018 to September 2019. Seventy-eight PD patients who were treated with safinamide of which 25 (32.05%) had a concomitant treatment with an antidepressant drug, being sertraline and escitalopram the most frequent. Mean age was 80 years ± 8.43 and H&Y stage was 3 [2–4]. Mean dose of levodopa used was 703.75 mg ± 233.15. Median duration of concomitant treatment with safinamide and antidepressant drug was 6 months (IQR 20.5), and over eighteen months in 5 cases. No case of serotonin syndrome was recorded, neither was any of its typical manifestations combined or in isolation.

Conclusions

Our real clinical practice study suggests that concomitant use of safinamide with antidepressant drugs in PD patients seemed to be safe and well tolerated, even in the long term. However, caution is warranted, individualizing treatment regimens and monitoring the potential appearance of adverse effects.

沙芬那胺和抗抑郁药物的联合治疗:来自临床实践的安全性数据
背景和目的 本研究旨在评估沙芬胺与抗抑郁药之间可能存在的药理相互作用,特别是通过实际生活中的数据评估血清素综合征的出现。方法 我们对运动障碍科的帕金森病患者进行了一项回顾性观察研究,这些患者正在接受任何抗抑郁药和沙芬胺的治疗。我们特别筛查了提示血清素综合征的症状。同时,我们还收集了同时使用左旋多巴和其他抗帕金森药物的时间、剂量。结果回顾了2018年9月至2019年9月研究期间的临床记录。78名帕金森病患者接受了沙芬那胺治疗,其中25人(32.05%)同时接受了抗抑郁药物治疗,其中最常见的是舍曲林和艾司西酞普兰。平均年龄为80岁(±8.43)岁,H&Y分期为3期[2-4]。左旋多巴的平均使用剂量为 703.75 毫克(± 233.15)毫克。同时使用沙芬那胺和抗抑郁药物治疗的中位时间为 6 个月(IQR 20.5),其中 5 例超过 18 个月。结论我们的实际临床实践研究表明,帕金森病患者同时使用沙芬那胺和抗抑郁药物似乎是安全和耐受性良好的,即使在长期治疗中也是如此。然而,在制定个体化治疗方案和监测可能出现的不良反应时仍需谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
53 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信